Similar articles for PMID: 21524253

Year	Number of Results
1996	1
1997	1
1998	3
1999	1
2000	3
2002	3
2003	2
2004	9
2005	5
2006	2
2007	9
2008	8
2009	5
2010	5
2011	13
2012	5
2013	1
2014	5
2015	6
2016	8
2017	2
2018	8
2019	3
2020	6
2021	1
2022	3
2023	1
2024	0

1

Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

Bourgault S, Chatenet D, Wurtz O, Doan ND, Leprince J, Vaudry H, Fournier A, Vaudry D. Bourgault S, et al. Curr Pharm Des. 2011;17(10):1002-24. doi: 10.2174/138161211795589337. Curr Pharm Des. 2011. PMID: 21524253 Review.

2

PACAP as a neuroprotective factor in ischemic neuronal injuries.

Shioda S, Nakamachi T. Shioda S, et al. Peptides. 2015 Oct;72:202-7. doi: 10.1016/j.peptides.2015.08.006. Epub 2015 Aug 11. Peptides. 2015. PMID: 26275482 Review.

3

Protective effects of PACAP in ischemia.

Reglodi D, Vaczy A, Rubio-Beltran E, MaassenVanDenBrink A. Reglodi D, et al. J Headache Pain. 2018 Mar 2;19(1):19. doi: 10.1186/s10194-018-0845-3. J Headache Pain. 2018. PMID: 29500688 Free PMC article. Review.

4

Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide.

Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, Fournier A. Bourgault S, et al. Curr Med Chem. 2009;16(33):4462-80. doi: 10.2174/092986709789712899. Curr Med Chem. 2009. PMID: 19835562 Review.

5

Effect of PACAP in central and peripheral nerve injuries.

Tamas A, Reglodi D, Farkas O, Kovesdi E, Pal J, Povlishock JT, Schwarcz A, Czeiter E, Szanto Z, Doczi T, Buki A, Bukovics P. Tamas A, et al. Int J Mol Sci. 2012;13(7):8430-8448. doi: 10.3390/ijms13078430. Epub 2012 Jul 6. Int J Mol Sci. 2012. PMID: 22942712 Free PMC article. Review.

6

Pleiotropic and retinoprotective functions of PACAP.

Shioda S, Takenoya F, Wada N, Hirabayashi T, Seki T, Nakamachi T. Shioda S, et al. Anat Sci Int. 2016 Sep;91(4):313-24. doi: 10.1007/s12565-016-0351-0. Epub 2016 Jun 20. Anat Sci Int. 2016. PMID: 27324639 Review.

7

Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects.

Atlasz T, Szabadfi K, Kiss P, Racz B, Gallyas F, Tamas A, Gaal V, Marton Z, Gabriel R, Reglodi D. Atlasz T, et al. Ann N Y Acad Sci. 2010 Jul;1200:128-39. doi: 10.1111/j.1749-6632.2010.05512.x. Ann N Y Acad Sci. 2010. PMID: 20633141 Review.

8

Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model.

Lamine A, Létourneau M, Doan ND, Maucotel J, Couvineau A, Vaudry H, Chatenet D, Vaudry D, Fournier A. Lamine A, et al. Neuropharmacology. 2016 Sep;108:440-50. doi: 10.1016/j.neuropharm.2015.05.014. Epub 2015 May 22. Neuropharmacology. 2016. PMID: 26006268

9

Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases.

Lee EH, Seo SR. Lee EH, et al. BMB Rep. 2014 Jul;47(7):369-75. doi: 10.5483/bmbrep.2014.47.7.086. BMB Rep. 2014. PMID: 24856828 Free PMC article. Review.

10

Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.

Somogyvári-Vigh A, Reglodi D. Somogyvári-Vigh A, et al. Curr Pharm Des. 2004;10(23):2861-89. doi: 10.2174/1381612043383548. Curr Pharm Des. 2004. PMID: 15379674 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year